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Key Points
Estrogen-containing or progestin-only hormonal therapy is not associated with increased recurrent VTE risk in women on anticoagulant therapy
Abnormal uterine bleeding occurred more frequently with rivaroxaban than with enoxaparin/vitamin K antagonists
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Abstract
Women receiving vitamin K antagonists (VKAs) require adequate contraception because of the potential for fetal complications. It is unknown if the use of hormonal therapy, especially those containing estrogens, is associated with recurrent venous thromboembolism (VTE) during anticoagulation. Despite the absence of data, World Health Organization guidelines state that use of estrogen-containing contraceptives confers an "unacceptable health risk" during established anticoagulation for VTE. We compared the incidences of recurrent VTE and abnormal uterine bleeding with and without concomitant hormonal therapy in women aged <60 years who were receiving anticoagulation with rivaroxaban or enoxaparin/VKA for confirmed VTE. Incidence-densities in %/year were computed for the 'on' and 'off' estrogencontaining or progestin-only therapy periods. Cox regression models were fitted, with hormonal therapy ('on' versus 'off') as a time-dependent variable to derive the hazard ratio (HR) for the effects on recurrent VTE and abnormal uterine bleeding. In total, 1888 women were included. VTE incidence-densities 'on' and 'off' hormonal therapy were 3.7%/year and 4.7%/year (adjusted HR 0.56; 95% confidence interval [CI] 0.23-1.39), respectively, and were 3.7%/year and 3.8%/year, respectively, for estrogen-containing and progestin-only therapy.
The adjusted HR for all abnormal uterine bleeding ('on' versus 'off' hormonal therapy) was 1.02 (95% CI, 0.66-1.57). Abnormal uterine bleeding occurred more frequently with rivaroxaban than with enoxaparin/VKA (HR 2.13; 95% CI, 1.57-2.89). Hormonal therapy was not associated with an increased risk of recurrent VTE in women receiving therapeutic anticoagulation. The observed increased risk of abnormal uterine bleeding with rivaroxaban needs further exploration.
Introduction
Patients with acute deep vein thrombosis (DVT) or pulmonary embolism (PE) require anticoagulation to prevent recurrent venous thromboembolism (VTE). 1 In women of childbearing potential who receive anticoagulation with vitamin K antagonists (VKAs), adequate contraception is required because these drugs cross the placenta, potentially leading to bleeding in the fetus and/or severe embryopathy. [2] [3] [4] Likewise, adequate contraception is indicated for women receiving direct oral anticoagulants owing to the ability of these small molecules to cross the placenta, potentially causing fetal bleeding and as yet unknown adverse effects on fetal development.
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There is reluctance among physicians to prescribe estrogen-containing contraceptives or postmenopausal hormone replacement to women who use anticoagulants for VTE because of the documented increased risk of VTE with these hormonal agents. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] 
Indeed, assessment of uterine bleeding in women using anticoagulants is important because cessation of hormonal therapy may contribute to increased uterine blood loss, whereas its use could be an option to prevent or treat uterine blood loss. 18 A recent meta-analysis suggested that use of rivaroxaban, apixaban, and ximelagatran for acute or extended VTE treatment was associated with an increased rate of bleeding in women.
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Therefore, we used the large EINSTEIN DVT and PE study cohort to compare the incidences of recurrent VTE and abnormal uterine bleeding in women with and without concomitant hormonal therapy receiving anticoagulant treatment with either rivaroxaban or enoxaparin/VKAs for confirmed symptomatic DVT and/or PE.
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Patients and methods
Between 2007 and 2011, the EINSTEIN DVT and PE trials evaluated the efficacy and safety of 3-, 6-, or 12-month courses of oral rivaroxaban versus subcutaneous enoxaparin overlapping with and followed by VKA therapy in patients with acute symptomatic DVT, PE, or both. Patients were followed for the intended treatment period and assessed at fixed intervals that were identical in the two treatment groups. At each visit, patients were systematically questioned for symptoms or signs of recurrent VTE and bleeding, including uterine bleeding.
In cases of suspected recurrent DVT/PE, a work-up using objective diagnostic tests was required. Symptomatic recurrent VTE was defined as a composite of fatal or nonfatal DVT or PE. 20, 21 All suspected recurrent venous thromboembolic events were reviewed by the central independent adjudication committee. All investigator-reported abnormal uterine bleeding and uterine bleeding leading to at least one unit of blood transfusion were collected. Details on 
All analyses took into account only women <60 years of age (two patients with gender reassignment were excluded) and were performed for 'all hormonal therapies' and for 'estrogen-containing therapy' (i.e. estrogen-only or combined) and 'progestin-only therapy', separately. Hysterectomized women were removed from the analyses of uterine bleeding.
Incidence-densities in %/year and corresponding 95% confidence intervals (CIs) were computed for the 'on' and 'off' hormonal therapy periods. Then, Cox regression models were fitted, with hormonal therapy ('on' versus 'off') as a time-dependent variable, to derive the hazard ratio (HR) and corresponding 95% CI for the effects of hormonal therapies on the rates of recurrent VTE; any abnormal uterine bleeding; and uterine bleeding leading to transfusion. All Cox models were stratified for age (20-year groups) and adjusted for prior use of hormonal therapy and assigned anticoagulant treatment. For recurrent VTE, an additional adjustment was made for any cancer at baseline, while for abnormal uterine bleeding additional adjustments were made for baseline presentation with anemia and gynecological disorders (i.e., uterine fibroids, adenomyosis, gynecological cancer, and/or history of abnormal uterine bleeding). P-values for interaction between anticoagulant treatment and hormonal therapy were calculated.
The EINSTEIN DVT (NCT00440193) and PE (NCT00439777) studies were conducted in a manner consistent with the principles of the Declaration of Helsinki. Institutional review board approval was obtained in all participating centers and all patients provided written informed consent. The data were collected and maintained by the sponsor. All suspected outcome events were classified by a central adjudication committee whose members were unaware of the treatment assignments. Drs Martinelli, Lensing, Gebel, and Prins had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Results
In total, 1888 women aged <60 years included in the EINSTEIN DVT and PE program qualified for these analyses. Of these women (mean age 41.3 years), 925 received rivaroxaban and 963 enoxaparin/VKA. Of the 705 women (37.3%) who were receiving hormonal therapy when their DVT and/or PE was diagnosed, 303 had stopped all hormonal therapy at the time of randomization. Thus, 402 women used hormonal therapy at some time during the analysis period. Of the 1183 women who were not using any hormonal therapy when their DVT and/or PE was diagnosed, 73 (6.2%) started hormonal therapy during the analysis period. Baseline characteristics in relation to hormonal therapy use after randomization are shown in Table 1 . Women who used hormonal therapy were younger and less frequently had active cancer or a history of VTE. Accumulated patient-years at risk with and without hormonal therapy for recurrent VTE, all abnormal uterine bleeding, and uterine bleeding leading to transfusion are shown in Tables 2-4 , respectively.
Recurrent venous thromboembolism
A total of seven recurrent venous thromboembolic events occurred during the use of hormonal therapy, whereas 38 events occurred during the period without use, giving crude incidence-densities of 3.7%/year on hormonal therapy and 4.7%/year off such therapy, for an adjusted HR of 0.56 (95% CI, 0.23-1.39). Sensitivity analyses using lag periods after stopping hormonal therapy of 14, 21, and 28 days did not create any important changes in the results. The crude incidence-densities for estrogen-containing and progestin-only therapy were 3.7%/year and 3.8%/year, respectively. Recurrent VTE occurred at approximately the same rate for rivaroxaban-and enoxaparin/VKA-treated patients (P interaction = .40). Incidencedensities for important subgroups are given in Table 2 . Considering ethinylestradiolcontaining therapy only, four recurrent venous thromboembolic events occurred during 100.3 patient-years (4.0%/year; 95% CI, 1.1-10.2).
Abnormal uterine bleeding
Excluding women who had undergone a hysterectomy, a total of 1737 women were evaluated, of whom 463 used hormonal therapy. A total of 37 (28 receiving estrogen and nine progestin-only) events of abnormal uterine bleeding occurred during hormonal therapy, whereas 148 events occurred during the period without use, giving crude incidence-densities of 22.5%/year on hormonal therapy and 21.4%/year off such therapy (Table 3) , for an adjusted HR of 1.02 (95% CI, 0.66-1.57). The crude incidence-densities for estrogencontaining and progestin-only therapy were 28.9%/year and 13.3%/year, respectively.
Abnormal uterine bleeding occurred more often in rivaroxaban-treated women compared with enoxaparin/VKA-treated women (HR 2.13; 95% CI, 1.57-2.89). The incidence-density of abnormal uterine bleeding during hormonal therapy was 29.8%/year for rivaroxaban recipients and 15.5%/year for enoxaparin/VKA recipients, whereas these values were 30.7%/year and 13.4%/year, respectively, without hormonal therapy (P interaction = .68).
Incidence-densities for important subgroups are given in Table 3 . Abnormal uterine bleeding resulted in interruption or permanent discontinuation of study anticoagulation in three (8.1%) of the 37 events that occurred during hormonal therapy and 19 (12.8%) of the 148 events that occurred without hormonal therapy.
Uterine bleeding leading to transfusion
A total of three uterine bleeding events leading to transfusion occurred during use of hormonal therapy, whereas 19 events occurred during the period without use, for crude incidence-densities of 1.6%/year on hormonal therapy and 2.5%/year off such therapy (Table   4 ; P interaction = .28).The HR could not be calculated owing to the low number of events. The crude incidence-densities for estrogen-containing and progestin-only therapy were 1.9%/year and 1.3%/year, respectively. Uterine bleeding that led to transfusion occurred more often in rivaroxaban-treated women (n = 19) compared with enoxaparin/VKA-treated women (n = 3).
Twenty of the 22 women with uterine bleeding leading to transfusion had anemia 
(hemoglobin <12 g/L) at baseline and nine had uterine fibroids and/or adenomyosis.
Incidence-densities for important subgroups are shown in Table 4 .
Results in subgroups according to hormonal therapy
In women using ethinylestradiol-containing hormonal therapy, four recurrent venous thromboembolic events occurred during 100. 
Discussion
This analysis of women treated with anticoagulants for acute VTE showed a similar rate of recurrent VTE in those who did and did not receive hormonal therapy. Moreover, the upper limit of the 95% CI around the observed point estimate of the HR excludes a clinically important difference in recurrent VTE. Consistent results were observed for estrogencontaining and progestin-only therapies. These results challenge the WHO guidelines, 16 and instead support the ISTH recommendations.
including the levonorgestrel intrauterine system, is often prescribed to prevent or treat menorrhagia. Almost all women who had uterine bleeding leading to transfusion had anemia at baseline. The incidence-densities of all abnormal uterine bleeding and those leading to transfusion were more frequent among rivaroxaban recipients compared with women treated with enoxaparin/VKA.
The observed increased risk of abnormal uterine bleeding with rivaroxaban compared with enoxaparin/VKA treatment is compatible with the earlier observation of increased rates of bleeding in women receiving treatment with rivaroxaban, apixaban, or ximelagatran. 
antifibrinolytic agents could be considered, because in general these agents have not been
shown to increase the risk of thrombosis.
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Some limitations of our study should be noted. Firstly, the EINSTEIN DVT and PE studies used an open-label design that could have biased assessment of outcomes. Nevertheless, efforts were made to limit investigator bias, including the requirement to use objective and validated tests to confirm suspected recurrent VTE and the use of an independent adjudication committee that was blinded to treatment assignment and use of concomitant medication. Secondly, our analyses were not pre-specified in the protocol or statistical analysis plan. However, data on concomitant medication were collected and monitored prospectively, and the protocol required only adequate contraceptive measures without further specification. Therefore, it cannot be excluded that women who were perceived to be at low risk of recurrent VTE were more likely to receive hormonal therapy. However, it is unlikely that such selection of patients played an important role, because the incidence of recurrent VTE was low and is hard to predict during anticoagulation. Thirdly, the screening and definition for uterine bleeding did not include qualitative or quantitative measures and, therefore, was potentially subject to reporting bias. However, following the National Institute for Health and Care Excellence (NICE) guidance recommendations on heavy menstrual bleeding, 32 we believe that the subjectivity of the assessment of menstrual bleeding can even be regarded as a strength of our study. While only the most severe cases of abnormal uterine bleeding may result in hospitalization, transfusion or even hysterectomy, it is also clear that the much more common bleeding complications of lesser intensity may have a significant impact on the patent's quality of life. In 2007, the NICE guidance paper stated that "heavy menstrual bleeding should be recognized as having a major impact on a woman's quality of life, and any intervention should aim to improve this rather than focusing on menstrual blood loss". Therefore, the inclusion of patient-reported events that may not have fulfilled a standardized menstrual bleeding scale may have resulted in a much more balanced view on the overall impact of abnormal uterine bleeding in patients receiving oral
anticoagulation. Fourthly, analyses were not adjusted for the use of antiplatelet therapy or non-steroidal anti-inflammatory drugs because their use could be influenced by the experienced severity of (normal) menstrual bleeding. 33 Fifthly, in the rivaroxaban arm, most uterine bleeding occurred during the first month of treatment when the dose of rivaroxaban was highest (30 mg versus 20 mg daily). However, a similar pattern over time for bleeding in the comparator arm and for recurrent VTE in both treatment arms was observed, congruent with observation with virtually all studies on the treatment of acute VTE. 42 Finally, because this was a post-hoc analysis, the pre-or postmenopausal status of women and their indication for hormonal therapy was not specifically documented. The reported average age of menopause is approximately 50 years with a range between 40 and 60 years. Since we wanted to document the hormonal therapy related risk of recurrent VTE in premenopausal women, we chose the cut-off age of 40 years for the subgroup analysis to ensure that virtually all women included in that analysis would be premenopausal. An increase of this age limit would inherently lead to the inclusion of an incremental number of postmenopausal women, potentially confounding the analysis. Moreover, it is important to realize that during anticoagulant treatment for VTE, age has never been identified as a risk factor for recurrent VTE. Hence, our analyses in women below 40 years of age can be regarded as the best estimate currently available on the risk of recurrent VTE during anticoagulation and hormonal therapy.
During the conduct of our study, the WHO guidelines on the use of hormonal therapy during anticoagulation were issued, which might have impacted physicians' choices. 16 Although all our calculations of the relative effects of hormonal therapy were adjusted for age, prerandomization use of hormonal therapy, presence of cancer, and, additionally, for anemia at baseline and gynecological disorders for the analyses of abnormal uterine bleeding, residual
confounding cannot be excluded. Furthermore, incidence-densities were used although it is known that the risk of recurrent VTE is highest during the first months. However, this pattern did not differ between women who did or did not use hormonal therapy, and Cox models with
time-dependent variables were used to calculate relative effects. A final limitation was the absence of a formal sample size calculation. However, the upper limit of the 95% CI of the observed HR of recurrent VTE in women using hormonal therapy was 1.39, which compared favorably with the a priori specified threshold for non-inferiority ( 
In conclusion, there is no indication that the use of estrogen-containing or progestin-only hormonal therapy is associated with an increased risk of recurrent VTE in pre-or postmenopausal women on anticoagulant treatment. The finding that use of rivaroxaban was associated with an increased rate of abnormal uterine bleeding needs further mechanistic exploration. Physicians should pay special attention to women with anemia or those with uterine fibroids or adenomyosis who start anticoagulant therapy.
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 
is an advisor to the UK Government Health Select Committee, the all-party working group on thrombosis, the Department of Health, and the NHS, on the prevention of VTE. A.T.C. is also an advisor to Lifeblood: the thrombosis charity and is the founder of the European Milan, Italy; e-mail: martin@policlinico.mi.it.
For For personal use only. on September 14, 2017. by guest www.bloodjournal.org From For personal use only. on September 14, 2017. by guest www.bloodjournal.org From 
(%) † BMI, body mass index; NSAID, non-steroidal anti-inflammatory drug; SD, standard deviation.
* Some patients received estrogen-containing and progestin-only therapies consecutively. † Defined as presence at baseline of uterine fibroids/adenomyosis, gynecological cancer, and/or abnormal uterine bleeding.
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